A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGFβ3 Antibody, in Healthy Volunteers.
Lyrialle W HanSamira JamalianJoy C HsuX Rebecca ShengXiaoyun YangXiaoying YangSharareh MonemiSharmeen HassanRajbharan YadavKatie TuckwellRebecca KunderLin PanSara GlicksteinPublished in: Rheumatology and therapy (2024)
ISRCTN13175485.